These ligands specifically bind to CD11b/CD18 receptors expressed on myeloid-derived suppressor cells and tumor-associated macrophages, ensuring the selective delivery of these cells within the immunosuppressive microenvironment of the tumor. This evidence concerns the gene ITGB2 and neoplasm.